10-Q · May 7, 2026
Immix Biopharma's Q4 results show continued financial losses with an increasing net loss of $10.1M compared to $4.5M in the same quarter last year. The company reported no revenue and significant growth in R&D expenses.…
Earnings analysis · 10-Q
IMMX earnings analysis
Filed August 7, 2026 · Our reading of the company's report
The latest report
This 10-Q excerpt does not include the income statement, balance sheet, cash flow statement, or MD&A, so revenue, margins, EPS, cash generation, liquidity, and segment trends cannot be assessed. Management reported…
Read full summary
This 10-Q excerpt does not include the income statement, balance sheet, cash flow statement, or MD&A, so revenue, margins, EPS, cash generation, liquidity, and segment trends cannot be assessed. Management reported effective disclosure controls as of June 30, 2026 and no material litigation identified. The principal updated risk concerns the reliability and regulatory interpretation of interim clinical-trial data, while the company also disclosed a $135,000 restricted-share issuance and August 7, 2026 agreement amendments.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Controls assessed as effective
Management concluded that disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2026. The company also reported no changes during the quarter ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
-
$135,000 equity issuance for services
During the six months ended June 30, 2026, Immix issued 18,346 restricted common shares valued at $135,000 for investor-relations services. The issuance was made pursuant to a marketing-services agreement dated July 25, 2023.
-
No material litigation identified
The company stated that it was not aware of any legal proceedings or claims that would have an individually or collectively material adverse effect on its business, financial condition, or operating results as of the filing.
What to watch
-
Interim clinical data may not hold
The filing added specific emphasis that interim clinical-trial data may differ materially from final results as more data become available, and that regulators or other third parties may disagree with the company’s analyses. The risk could impair approval and commercialization of candidates, including NXC-201; this update is included in the June 30, 2026 quarter filing.
-
Shareholder dilution risk
The company issued 18,346 restricted shares valued at $135,000 for investor-relations services during the six months ended June 30, 2026. Further equity-based compensation or service issuances could dilute existing holders, although the filing does not quantify future issuances.
-
Management agreement changes
The company disclosed amendments dated August 7, 2026 to the CEO employment agreement and the management-services agreement with Alwaysraise, LLC. The filing provides no quantitative estimate of the related financial impact, creating uncertainty around future corporate and management expenses.
Management's outlook
No quantitative revenue or EPS outlook was provided in the extracted 10-Q. The filing does not provide explicit guidance; any outlook may be deferred to the earnings release or call.
Earlier filings 4
10-K · March 25, 2026
Immix Biopharma is a clinical-stage CAR-T company focused on NXC-201 for relapsed/refractory AL amyloidosis. The 10-K highlights strong interim Phase 2 efficacy (75% CR by IRC in 15/20 patients as of Nov 13, 2025),…
10-Q · November 7, 2025
Immix Biopharma reported no revenue and a quarterly net loss of $7,585,692 (loss per share $0.24) for the three months ended September 30, 2025. Cash declined to $15,947,308 and operating cash used was $12,900,697 for…
10-Q · November 12, 2024
Immix Biopharma reported a net loss of $7,149,395 (loss per share $0.24) for the three months ended September 30, 2024, driven by higher R&D and G&A spending. Cash and equivalents were $19,690,431 at September 30, 2024…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.